In a deal that could potentially be worth up to US$820 million, GlaxoSmithKline (GSK) has gained the exclusive, worldwide development and commercialization rights to retigabine, a first-in-class ...

GSK (GSK) and IDRx announced that they have entered into an agreement under which GSK will acquire IDRx. Under the agreement, GSK will pay $1B upfront, with potential for an additional $150M ...

In a statement, GlaxoSmithKline said it disagreed with some statements the Justice Department made in court papers. For example, the company said its settlement with the government does "not ...

Copyright © 2025 MarketWatch, Inc. All rights reserved.

In a report released today, Florent Cespedes from Bernstein maintained a Buy rating on GlaxoSmithKline (GSK – Research Report), with a price target of £23.55. The company’s shares closed ...

Copyright © 2024 MarketWatch, Inc. All rights reserved.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other FTSE dividend stocks. Goldman Sachs Research predicts moderate growth for the UK economy in 2025 ...

The FDA has started a review of GSK’s five-in-one meningococcal vaccine, cueing up a decision in mid-February next year, as it tries to chase down a rival candidate from Pfizer cleared last year.